1. ALLA AKTIER
  2. NYHETER
  3. NANOECHO

NanoEcho

Nyheter NanoEcho Nyheter alla bolag

NanoEcho has entered into an agreement securing the supply of nanoparticles

MAR

Today, NanoEcho has entered into a comprehensive agreement ensuring the company's access to iron oxide-based nanoparticles, Ferrotran® (ferumoxtran), both in the short and long term. The agreement with SPL Medical represents the company's most significant deal to date, as the choice of nanoparticles is crucial for the optimal functioning of the company's diagnostic method.

The business agreement, signed today by SPL Medical and NanoEcho, is a comprehensive contract. The agreement grants NanoEcho exclusivity regarding the supply of Ferrotran® (ferumoxtran), iron oxide-based nanoparticles for use in magnetomotive ultrasound. These nanoparticles are planned to be part of the system from which the company intends to generate revenue.

For the clinical effectiveness of the system, the choice of nanoparticles is of crucial importance. Ferrotran® is chosen based on its ability to spread in the lymphatic system and differentiate between diseased and healthy tissue in lymph node metastasis. NanoEcho has evaluated the unique lymphotropic properties in preclinical studies, and the results form the basis for the choice of this particle.

The agreement includes delivery for both the planned clinical study and future sales.

"Today, NanoEcho has successfully secured the supply of iron oxide-based nanoparticles through a comprehensive agreement with SPL Medical. This agreement is of utmost significance for our business and represents a significant milestone. The choice of these nanoparticles is critical for optimising our diagnostic method. We look forward to continuing to work with full focus on market approval and are very pleased with this significant step forward," says Dr. Linda Persson, CEO of NanoEcho.
"The choice of NanoEcho for the SPL medical proprietary iron oxide nanoparticle Ferrotran® underlines its unique lymphatic properties and demonstrates the platform applicability of Ferrotran® over various applications and technologies beyond magnetic resonance imaging," says Dr. Jürgen Feuerstein, CEO of SPL Medical.

For further information, please contact:
Kristina Hallström, CMO & CCO
email: ir@nanoecho.se

This information is information that NanoEcho is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-02-27 15:45 CET.

SPL Medical is a spin-off of the Radboud University Medical Center and is funded additionally by Oost NL, a Dutch regional venture capital company, and b.e.imaging GmbH, a German company specialised in the development and commercialisation of contrast agents. SPL Medical is the manufacturer of Ferrotran® and is responsible for its worldwide commercialisation. The company has a multicentre phase III trial for the detection of lymph node metastases in prostate cancer patients for Ferrotran® (ferumoxtran) in major radiology/urology centres in Germany, Switzerland, the Netherlands and Belgium in an advanced status. www.ferrotran.com

NanoEcho develops a new technology for clearer diagnostics of, in the first indication, rectal cancer. The imaging technology is based on a new medical approach where nanotechnology is used in combination with modern patented ultrasound technology. The images that are generated are intended to facilitate differentiation between healthy and diseased tissue and at the same time determine the location of the cancer tissue more precisely. The aim is to provide more precise, simple, and cost-effective diagnosis of cancers and other diseases. With clearer diagnostics, the company wants to assist treating physicians with better guidance for more personalised treatment. Both the quality of life of the patients and their chance of survival can improve after treatment, with reduced treatment costs. www.nanoecho.se

Image Attachments
Dr. Linda Persson, CEO of NanoEcho, together with Dr. Jürgen Feurestein, CEO of SPL medical

Attachments
NanoEcho has entered into an agreement securing the supply of nanoparticles

Datum 2024-02-27, kl 15:45
Källa MFN
Bifogade filer
NanoEcho has entered into an agreement securing the supply of nanoparticles
Dr. Linda Persson, CEO of NanoEcho, together with Dr. Jürgen Feurestein, CEO of SPL medical
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!